Vis enkel innførsel

dc.contributor.authorMølstad, Per
dc.contributor.authorNordrehaug, Jan Erik
dc.contributor.authorSteigen, Terje
dc.contributor.authorWilsgaard, Tom
dc.contributor.authorWiseth, Rune
dc.contributor.authorRotevatn, Svein
dc.contributor.authorMannsverk, Jan Torbjørn
dc.contributor.authorLarsen, Tommy
dc.contributor.authorLarsby, Kristina
dc.contributor.authorSkarstad, Sigrun
dc.contributor.authorFosse, Eivind Øygard
dc.contributor.authorDahl-Eriksen, Øystein
dc.contributor.authorBønaa, Kaare Harald
dc.date.accessioned2022-04-01T11:49:30Z
dc.date.available2022-04-01T11:49:30Z
dc.date.issued2021-01
dc.description.abstractBackground: Drug-eluting stents (DES) reduce target lesion revascularization (TLR) with no effect on mortality or myocardial infarction (MI) compared to bare-metal stents (BMS) in native vessels. Randomized stent studies in saphenous vein grafts (SVG) are few and the reported effects are ambiguous. The Norwegian Coronary Stent Trial study is the first to randomize lesions to percutaneous coronary intervention in native vessels and SVG. Aims: The aim of this study was to compare the rate of mortality, MI, and TLR across stent and vessel types. Methods: In this substudy, 6,087 patients with a single lesion in native vessels and 164 in SVG were followed for 5 years. Results: MI was more frequent in SVG (subdistributional hazard ratio [SHR] 4.95 (3.75–6.54, p < 0.001), but not affected by stent type. In the first 500 days, DES reduced TLR in native vessels (SHR 0.21 (0.15–0.30) p < 0.001) and SVG (SHR 0.18 (0.04–0.80) p = 0.02). Thereafter, DES and BMS were equivalent in native vessels, but DES had a higher TLR rate than BMS in SVG (SHR 3.31 (1.23–8.94) p = 0.02). After 5 years, the TLR rate was still significantly lower for DES in native vessels (3.2% vs. 7.8%, p < 0.001) but not in SVG (21.4% vs. 18. 4%). Conclusion: In SVG, no difference in TLR between DES and BMS was observed after 5 years in contrast to persistent benefit in native vessels. The high rate of TLR and MI in SVG makes treatment of native vessels a preference whenever feasible and better treatment options for SVG are warranted.en_US
dc.descriptionThis is the accepted manuscript version of an article published by S. Karger AG in Cardiology. 2021;147:14-22; https://doi.org/10.1159/000521085.en_US
dc.identifier.citationMølstad, Nordrehaug JE, Steigen, Wilsgaard, Wiseth, Rotevatn, Mannsverk, Larsen, Larsby K, Skarstad, Fosse, Dahl-Eriksen, Bønaa. Drug-Eluting versus Bare-Metal Stents in Saphenous Vein Grafts Compared to Native Coronary Vessels: The Norwegian Coronary Stent Trial Study. Cardiology. 2021;147:14-22en_US
dc.identifier.cristinIDFRIDAID 2000901
dc.identifier.doi10.1159/000521085
dc.identifier.issn0008-6312
dc.identifier.issn1421-9751
dc.identifier.urihttps://hdl.handle.net/10037/24680
dc.language.isoengen_US
dc.publisherKarger Publishersen_US
dc.relation.journalCardiology
dc.rights.accessRightsopenAccessen_US
dc.rights.holder© 2021 S. Karger AG, Baselen_US
dc.titleDrug-Eluting versus Bare-Metal Stents in Saphenous Vein Grafts Compared to Native Coronary Vessels: The Norwegian Coronary Stent Trial Studyen_US
dc.type.versionacceptedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel